Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

GSK-3915393

Alternative Names: gsk-3915393, gsk 3915393, gsk3915393
Latest Update: 2025-02-18
Latest Update Note: Clinical Trial Update

Product Description

Gsk-3915393 is a Transglutaminase 2 (TG2) inhibitor under development by GlaxoSmithKline for treatment of Celiac Disease in Phase 1. (Sourced from: https://www.gsk.com/en-gb/research-and-development/our-pipeline/)

Mechanisms of Action: TG2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-3915393

Countries in Clinic: Argentina, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Idiopathic Pulmonary Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT06317285

P2

Recruiting

Idiopathic Pulmonary Fibrosis

2026-03-24

220929

P2

Unknown Status

Idiopathic Pulmonary Fibrosis

2026-03-19

NCT06625489

P1

Completed

Idiopathic Pulmonary Fibrosis

2024-11-25

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions